Description

Ponesimod-d4 (ACT-128800-d4)is the deuterium labeledPonesimod(HY-10569)[1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].–Applications-Neuroscience-Neuromodulation-Formula-C23H21D4ClN2O4S-Citation–References-[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber–MolecularWeight-465.00-Compound Purity–SMILES-O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2C)/C(S/C1=CC3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC-Research_Area-Others-Solubility-10 mM in DMSO-Target-Isotope-Labeled Compounds;LPL Receptor-Isoform–Pathway-GPCR/G Protein;Others-MCE Product type-Isotope-Labeled Compounds